Published Date: 08 Mar 2023
Australia has the potential to become the first country in the world to eliminate cancer as a public health problem.
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.
2.
Advanced breast cancer patients living longer thanks to improvements in treatment and care
3.
Beyond What Is Visible in Myelofibrosis?
4.
Early-Onset Colorectal Cancer in Male Veterans is Predicted by Risk Factors.
5.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas
3.
All You Need to Know About Mesna: The Ultimate Guide
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Efficient Management of First line ALK-rearranged NSCLC - Part II
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation